Patent 10406366 was granted and assigned to Respicardia, Inc. on September, 2019 by the United States Patent and Trademark Office.
A lead system and method of use for treating breathing disorders by the transvenous stimulation of the phrenic nerve. The lead is implanted in a vein near one portion of the phrenic nerve.